共 154 条
- [1] Honore C(2015)Soft tissue sarcoma in France in 2015: epidemiology, classification and organization of clinical care J Visc Surg 152 223-230
- [2] Méeus P(2013)Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project Eur J Cancer 49 684-695
- [3] Stoeckle E(2017)Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial Lancet Oncol 18 812-822
- [4] Bonvalot S(2012)Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group J Clin Oncol 30 850-856
- [5] Stiller CA(2014)Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial Lancet Oncol 15 415-423
- [6] Trama A(1992)High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma J Clin Oncol 10 52-60
- [7] Serraino D(2000)Limb salvage by neoadjuvant isolated perfusion with TNFα and melphalan for non-resectable soft tissue sarcoma of the extremities Eur J Surg Oncol EJSO 26 669-678
- [8] Rossi S(1984)Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system Int J Cancer 33 37-42
- [9] Navarro C(1982)Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions Eur J Cancer Clin Oncol. 18 905-910
- [10] Chirlaque MD(1996)Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience Ann Surg. 224 756-2241